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Epidermodysplasia verruciformis-associated human
papillomaviruses and in particular human papil-
lomavirus type 5 were recently shown to be highly
prevalent in psoriatic skin. We have analyzed lesional
skin from 54 psoriasis patients for infections with
genital-specific and epidermodysplasia verruciformis-
specific human papillomaviruses to define the spec-
trum of involved human papillomavirus types and to
test if it is influenced by psoralen ultraviolet A therapy.
Using polymerase chain reaction analysis we could
detect human papillomavirus sequences in skin lesions
of 83% of the tested patients. In contrast, human
papillomavirus-DNA was only demonstrated in 19%
of skin samples from 42 dermatologically healthy,
immunocompetent individuals. Sequence analysis of
the polymerase chain reaction amplimers revealed 14
human papillomavirus types, all belonging to the
epidermodysplasia verruciformis or epidermodyspla-
sia verruciformis-related papillomaviruses. Only in
one case we identified sequences related to those of
genital viruses, which, however, represented a putat-
ively new human papillomavirus type. The most pre-
Human papillomaviruses (HPV) are etiologic agentsof many epithelial tumors in humans. A broadspectrum of HPV-induced pathologies ranges fromcommon warts to neoplastic lesions of the cervix uteri(Shah and Howley, 1996; Gross and Barasso, 1997).
Numerous recent studies reported on the presence of HPV
sequences in precancerous and malignant skin tumors (for review
see Pfister and ter Schegget, 1997). A particularly high prevalence
of HPV-DNA could be demonstrated in skin tumors of immuno-
suppressed transplant recipients. Surprisingly, a substantial propor-
tion of involved HPV types turned out to belong to the large
group of HPV types, originally believed to be exclusively associated
with tumors of epidermodysplasia verruciformis (EV) patients (Orth,
1987; Fuchs and Pfister, 1996). The EV syndrome is a rare, lifelong
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valent human papillomavirus type in our patient series
was human papillomavirus type 36, found in 62% of
the patients positive for human papillomavirus-DNA,
followed by human papillomavirus type 5 (38%) and
human papillomavirus type 38 (24%). Multiple infec-
tions with two to five different human papillomavirus
types could be detected in skin samples of 63% of the
analyzed patients. The overall human papillomavirus
detection rate did not differ significantly between
patients which have been subjected to psoralen ultra-
violet A photochemotherapy or solely treated with
topical preparations (77 vs 89%). Human papilloma-
virus type 5, however, could be detected significantly
more frequent in lesions of psoralen ultraviolet
A-treated patients (p < 0.001). Our data strongly argue
for infections with epidermodysplasia verruciformis-
specific papillomaviruses being an almost consistent
feature of the lesional psoriatic skin and substantiate
the importance of further studies to elucidate a possible
involvement of human papillomaviruses in psoriasis
pathology. Key words: epidermodysplasia verruciformis/
human papillomavirus/psoriasis/psoralen ultraviolet A. J
Invest Dermatol 113:122–126, 1999
persisting skin disease which depends on some still not characterized
defect(s) of the cell-mediated immunity (Orth, 1987; Jablonska and
Majewski, 1994). EV patients develop multiple flat warts and
macular skin lesions which will frequently give rise to squamous
cell carcinomas. The specific cytopathic effects of EV-associated
HPV have only sporadically been observed apart from the EV
syndrome but seroepidemiologic studies always suggested a wide-
spread occurrence of EV–HPV in the general population (Steger
et al, 1990; Stark et al, 1998). This was substantiated by the
demonstration of EV-specific HPV-DNA in many normal skin and
plucked hair samples (Astori et al, 1998; Boxman et al, 1997).
Sequencing of polymerase chain reaction (PCR) amplification
products from such specimens and from skin tumors of non-EV
patients revealed classical EV-specific types but also to a large extent
putatively new, EV-related types (Berkhout et al, 1995; Shamanin
et al, 1996; Bens et al, 1998). The spectrum of HPV types thus
differed from EV patients and particularly HPV5 and HPV8, which
are most prevalent in EV, were only rarely detected (Pfister and
ter Schegget, 1997).
An extraordinary high prevalence of EV–HPV has recently been
reported for skin lesions of psoriasis patients (Favre et al, 1998a).
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Table I. Detection of HPV-DNA in samples of normal and psoriatic skin
Tested specimens PCR primers (% positives)
GP51/61 CP 70/65-69/66 HPV5 type specific HPV36 type specific Total positive
Skin lesions from (n 5 54) 0a 70 30 52 83
psoriatic patients n 5 0b n 5 38 n 5 16 n 5 28 n 5 45
Skin specimens from (n 5 42) 0 14 0 10 19
healthy donors n 5 0 n 5 6 n 5 0 n 5 4 n 5 8
aPercent possible samples.
bAbsolute number of positive samples.
Table II. Frequency of detection of individual HPV types
in psoriatic lesions






RTRX1, 19 5 11
23, 24, 25 3 7
8, 9, 15, 20 2 4
RTRX7 1 2
Unknown type (SW1) 1 2
HPV5 turned out to be the most prominent type, followed by
HPV36, HPV20, and HPV38. Psoriasis is a noncontagious
dermatosis with genetic predisposition, occurring world-wide with
morbidity rates of 1.5–2% in caucasians (Christophers, 1996). In
most of the cases, the disease persists lifelong with many recurrent
episodes, induced by a broad variety of different factors. The
pathogenesis of psoriasis is still unclear, although it certainly involves
T cell mediated inflammatory reaction(s) which results in promotion
of the uncontrolled regenerative epidermal proliferation
(Christophers, 1996; Griffiths and Voorhees, 1996). The nature of
factor(s) or antigen(s), responsible for priming the involved T
lymphocytes is still a matter of controversy (Majewski et al, 1998;
Nickoloff and Wrone-Smith, 1998). In view of the new virologic
data on psoriasis Majewski et al (1998) hypothesized that the major
capsid protein of HPV5 may play a part as putative autoantigen
active in immunopathology of psoriasis.
A widely used and generally highly effective anti-proliferative
treatment in psoriasis consists of topical or systemic administration
of psoralen, followed by irradiation with UVA light (PUVA).
Both these agents can potentially influence interactions between
keratinocytes and the infecting HPV. In order to evaluate this
relationship and to characterize the spectrum of the involved HPV
types we studied a collective of 54 psoriasis patients treated or not
treated with PUVA for the presence of HPV-DNAs in their
lesional skin.
MATERIALS AND METHODS
Patients and biopsy material Biopsy material from lesional skin of 54
psoriasis patients was obtained to verify the diagnosis. The majority of
studied patients (n 5 48) originated from Tirol, Austria, the remaining six
cases were from Poland. The patients were immunocompetent individuals
with a mean age of 48.5 y (range 17–74) and presented with typical skin
lesions of chronic stationary plaque (n 5 44), acute eruptive guttate (n 5
3), pustular (n 5 2), or arthropathic (n 5 3) psoriasis. The medication
consisted of topical steroids, dithranol preparations, and retinoids, combined
or not with PUVA. In the latter regimen doses of 10–500 J per cm2 were
applied in most of the cases (22 patients). Only four patients were treated
with high cumulative PUVA doses. Therapy with . 2000 J per cm2 was
initiated in these cases more than 20 y ago, before emergence of squamous
cell carcinoma of the skin was first reported as an adverse effect in PUVA
patients in 1979 (Morison et al, 1998). All specimens were taken from
active lesions at the beginning of a new disease/therapy episode. The
control group consisted of 42 healthy, immunocompetent individuals
undergoing nevus excisions (mean age 43.0 y, range 16–79). All specimens
showed a normal epidermis on histologic examination with nevus cells in
the basal layer, junctional zone, or deeper dermis. No changes suggestive
of HPV infection were present in the excised skin clinically or histologically.
Patients neither suffered from diseases associated with immunosuppression
or immunosuppressive therapy nor were therapeutic UV irradiations
reported in the patients’ history.
DNA extraction Total cellular DNA was extracted from biopsies
using the QIAmp Tissue Kit (Qiagen, Hilden, Germany) according to
manufacturer’s protocol. The quality of each DNA preparation was
controlled by a PCR test for the cellular β-globin gene (Saiki et al, 1985)
and only positive cases have been included in further analyses.
Detection of HPV sequences DNA preparations were examined for
the presence of HPV sequences by PCR analysis with primers, chosen to
detect a broad spectrum of HPV types. The two primer sets used were:
GP51/GP61 (De Roda Husman et al, 1995), specific for HPV types
typically infecting the genital mucosa and CP65/CP70 1 CP66/CP69,
designed by Berkhout et al (1995) as a nested PCR approach for the
detection of EV-associated papillomaviruses. The presence of HPV5-DNA
and HPV36-DNA in biopsy material was re-evaluated in all cases by means
of a type-specific PCR test according to Favre et al (1998a). The DNA
amplification was performed with 100–400 ng template and AmpliTaq
Polymerase (Perkin-Elmer, Langen, Germany) in the Mastercycler 5330
(Eppendorf, Hamburg, Germany) according to protocols, published for all
the primer pairs used. To avoid contamination of samples during DNA
preparation and the PCR processing, the suggestions of Kwok (1990) were
strictly observed.
DNA sequencing For sequence analysis PCR amplimers were prepara-
tively separated in 2% agarose gels, the specific bands excised and the DNA
was purified using the QIAquick gel extraction kit (Qiagen, Hilden,
Germany). The isolated DNA fragments were cloned into the pCR-Blunt
vector (Invitrogen, De Schelp, the Netherlands), transformed in Escherichia
coli TOP10 cells and the recombinant bacterial clones were isolated due
to a highly specific anti-suicidal selection. Plasmids from at least 10 colonies
each were digested with EcoRI to release the cloned inserts. Representative
clones showing both the expected and deviating inserts have been subjected
to sequence analysis. Sequencing was performed with the Taq FS BigDye-
terminator cycle sequencing system using the ABI Prism 377 automatic
sequencer (Applied Biosystems, Langen, Germany).
Sequence analysis Sequence analyses were performed using the BLAST
2.0 (Altschul et al, 1997) and MacVector 6.5 (Oxford Molecular Group
PLC, U.K.) program packages. EMBL, GenBank, DDJB, and PDB served
as sequence databases.
Statistical analysis Differences in DNA prevalences were evaluated by
χ2 and confidence interval (CI) analysis using the SPSS Base System,
version 6.1 (SPSS, Chicago, IL).
RESULTS
HPV sequences in clinical samples of psoriatic
skin Specimens of psoriatic skin lesions from 54 patients were
tested for the presence of HPV sequences by means of PCR
analysis. To cover a broad spectrum of HPV types, two sets of
PCR primers have been employed which preferentially detect
genital-specific and EV-specific papillomavirus types, respectively.
The results of the PCR screening are summarized in Table I.
Using the nested PCR approach with primers CP 70/65–69/66,
papillomavirus sequences could be found in 38 of 54 studied
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Table III. Distribution of HPV-DNA in skin lesions of PUVA-treated and nontreated patients
HPV-positive Number of HPV HPV5-positive HPV36-positive HPV38-positive HPV8-positive
cases types per person cases cases cases cases
Previous PUVA treatment 4 (100%) 3.8 3 (75%) 4 (100%) 1 (25%) 2 (50%)
. 2000 J per cm2 (n 5 4)
Previous PUVA treatment 16 (73%) 2.0 10 (46%) 12 (55%) 3 (14%) 0 (0 %)
ø 500 J per cm2 (n 5 22)
No PUVA treatment (n 5 28) 25 (89%) 1.5 3 (11%) 12 (43%) 7 (25%) 0 (0%)
Figure 1. Nucleotide-and protein-sequence alignment of SW1 and
MM8 within the PCR-amplified parts of their L1 genes. N: DNA
sequence, A: amino acid sequence according to the one letter-code. The
accession number of the PCR-amplified sequence of a putatively new
HPV type SW1 is AJ012757.
biopsies (70%), indicating a high prevalence of papillomavirus
infections in psoriatic skin. No HPV-DNA could be detected in
psoriatic lesion using the single-step PCR test with primers GP51/
GP61, specific for HPV types infecting the genital mucosa. In
view of the reported frequent occurrence of HPV5 and HPV36 in
the psoriatic dermis (Favre et al, 1998a), all cases were subsequently
analyzed by PCR tests with the corresponding type-specific primers.
These experiments revealed seven further cases being positive for
HPV-DNA, which led to a total HPV prevalence in the studied
psoriatic collective of 83%. The majority of tested specimens
represented typical psoriatic plaques. Also lesions of guttate (n 5
3), pustular (n 5 2), and arthropathic (one of three) psoriasis,
however, were positive for HPV-DNA.
In contrast, HPV-DNA could be detected only in 19% of random
biopsies from 42 dermatologically healthy, immunocompetent
subjects.
A variety of HPV types infects skin lesions of psoriasis
patients In order to classify HPV types detected in psoriatic skin,
all PCR amplimers were cloned and sequenced. As shown in
Table II, all, except one, identified HPV sequences represented
either well-known EV-associated papillomaviruses or related HPV
types of the RTRX-series, characteristic for skin tumors of immuno-
suppressed renal transplant recipients (Berkhout et al, 1995; Bens
et al, 1998). The most prevalent HPV types in the analyzed
collective were HPV36, HPV5, and HPV38, found in lesions of
62, 36, and 24% of the psoriasis patients, respectively. The additional
11 identified HPV types occurred in 2–13% of the analyzed patients.
A characteristic feature of the studied biopsies were common
multiple infections: in 39 of 54 cases (63%) 2–5 different HPV
types could be detected.
Analysis of the PCR-positive nevus excisions used as control
samples revealed only the presence of single infections with HPV
types 23, 25, and 36. HPV36 was identified in four of eight of
these specimens.
A comparison of sequences amplified in this study from a part
of the open reading frame L1 with those from available databanks
revealed no case of perfect identity. The individual sequences of
the most prevalent HPV36 showed, e.g., 97%–99% homology with
the reference isolate (Myers et al, 1997). These findings are in line
with the well-recognized genetic variability of HPV types. In one
of the tested psoriasis lesions a putatively new HPV type could be
identified (SW1). The 352 bp sequence determined from its L1
gene displayed over 329 bp 86.6% homology to MM8, an HPV
isolate from a case of cervical dysplasia (Manos et al, 1994; Fig 1).
In addition, 15 bp absent in the MM8 sequence coded in frame
for two inserts of three and two amino acid residues of the L1
protein, respectively. This presumably new virus type should belong
to genital mucosa-specific HPV of the phylogenetic group A3
(Myers et al, 1997).
HPV infections and photochemotherapy The tested collect-
ive consisted of two groups of psoriasis patients roughly equal
in number, which have or have not been treated by PUVA
photochemotherapy. As PUVA regimen can be expected to influ-
ence the course of an HPV infection, we examined the occurrence
of HPV-DNA in psoriatic skin lesions of both these patient groups
(Table III). The overall prevalence of HPV infections did not
significantly differ. Infections with multiple HPV types, however,
were significantly more frequent in PUVA-treated individuals (80%
vs 42% in PUVA nontreated persons; p 5 0.01, CI 0.12; 0.64).
There is also some indication that the average number of HPV types
per patient increases with PUVA treatment and doses (Table III).
Regarding the distribution of individual HPV types infecting the
lesional psoriatic skin, it turned out that in contrast to other
identified viruses, HPV5 could be detected almost 5-fold more
frequently in samples of the PUVA-medicated individuals
(p , 0.001; CI 0.30; 0.70). HPV8, which represents another EV
cancer-associated HPV type was detected twice only in the group
of patients treated with high doses of PUVA.
DISCUSSION
The results of our PCR screening demonstrated a very high
prevalence of HPV sequences in the psoriatic skin. More than 80%
of the tested patients scored positive with primers, which allow
detection of a broad spectrum of the genital and EV-associated
HPV types. The observed prevalence of HPV-DNA in psoriatic
lesions was 4.5 times higher than in samples from healthy individuals,
which strongly argues for a specific association of HPV infections
with psoriatic disease of the skin. The high HPV-DNA detection
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rate appears at least generally independent of photochemotherapy
because no significant differences could be observed between
patients who were and those who were not treated with PUVA.
These results are in line with data of Favre et al (1998a, b). They
could be explained by the increased epidermal proliferation rates
in psoriasis, which stimulate replication of the pre-existing HPV-
DNA in lesions and thus facilitate their subsequent detection.
The activated HPV might also be involved in the autoimmune
pathomechanism of psoriasis as had been proposed by Majewski
et al (1998).
Sequence analysis of the PCR amplimers identified 11 classical
EV-associated HPV types (5, 8, 9, 15, 19, 20, 23, 24, 25, 36, 38)
and three of their close relatives (RTRX1, 2, 9). A putatively new
sequence (SW1) was most closely related to MM8, which belongs
to subgroup A3 of the genital/mucosal HPV together with HPV
types 61, 62, and 72 (Myers et al, 1997). Besides appearing in
anogenital intraepithelial neoplasia, HPV61 was sporadically
detected in squamous cell carcinoma and Bowen’s disease of the
skin (Shamanin et al, 1996; Mitsuishi et al, 1997). More than one
HPV type was detected in over 60% of the patients. It has been
interesting to note that infections with three to five HPV types
preferentially occurred in PUVA-treated patients. This may point
to generally increased levels of viral DNA, allowing the detection
of HPV that persist besides the dominant type in individual patients.
In contrast to data of Favre et al (1998a), the dominating HPV
type in our patient series was HPV36 and not HPV5 (63% vs 37%).
HPV36 was also the most prevalent virus type in the skin samples
of healthy controls. Further, HPV38 could be found relatively
frequently (26%). It was originally isolated from a melanoma
(Scheuerlen et al, 1986), although a recent study failed to confirm
its association with melanoma tumors (Astori et al, 1998).
It is presently difficult to comment on the different prevalences
of individual HPV types reported by Favre et al (1998a) and in this
study. It should be kept in mind that despite identical PCR
protocols for the detection of HPV-DNA, the sensitivity for
individual types may be affected by technical differences such as
blot hybridization following PCR amplification (Favre et al, 1998a).
On the other hand it should be noted that both studies also differ
with regard to the origin of the analyzed collectives (Polish versus
mostly Tirolean patients). Last but not least, the patients may differ
in their natural life-time sun exposure and/or cumulative doses of
UV irradiation in the course of PUVA therapy.
Favre et al (1998b) observed no difference in HPV5 DNA
positivity among patients who were currently, previously or never
under PUVA therapy with doses between 1 and 212 J per cm2.
We found a 5-fold higher prevalence of HPV5 (p , 0.001),
however, but not HPV36 and HPV38 in skin lesions of patients
subjected to PUVA therapy. Given the high overall prevalence of
HPV5 (89%) it probably would have been impossible for Favre
et al (1998a,b) to reveal a statistically significant increase following
PUVA treatment. The HPV5 data could be reconciled by assuming
a higher load of viral DNA in PUVA-treated patients and differences
in the sensitivity of HPV5 detection in both studies.
Our data may indicate that photochemotherapy selectively favors
the replication of specific HPV types. In line with this hypothesis,
HPV5 DNA was detected in three of four patients subjected to
long-term, high-dose PUVA therapy (2000–3600 J per cm2). It is
interesting to note that HPV8, which is a close relative of HPV5
and known for its association with skin cancer in EV, was detected
twice in this patient group only. Coinciding with the preferential
detection of high-risk EV–HPV, two of the HPV5 positive patients
developed multiple squamous and basal cell carcinomas, which
were unfortunately not available for DNA analysis. HPV5 positive,
PUVA-associated nonmelanoma skin cancers, however, have been
described in psoriasis patients treated with high doses of UVA
(Bayle-Lebey et al, 1994; Harwood et al, 1998). There is clear
evidence that PUVA is a risk factor for skin cancer in psoriasis
patients. Apart from chemical cross-linking of DNA by psoralen
and subsequent UVA irradiation, light sources used in PUVA
therapy also emit a small but significant wavelength component in
the UVB region and both, UVA and UVB were shown to induce
p53 mutations (Nataraj et al, 1997). PUVA treatment also behaves
as an immunosuppressive in the skin. This may well offer another
explanation for the increased incidence of carcinomas in PUVA-
treated patients (Morison et al, 1998). Our data on increased
prevalence of high-risk EV-associated HPV following high-dose
PUVA therapy may suggest that these types further contribute to
cancer development.
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